August 10, 2022
Loading...
You are here:  Home  >  Health Care & Life Science  >  Current Article

Amgen launches Humira biosimilar in Europe

IN THIS ARTICLE

Amgen’s biosimilar Amgevita, an alternative to the world’s best-selling drug Humira, launched in European markets, the company announced Oct. 16. The launch follows a timeline for Amgevita’s release laid out by a settlement reached by the Thousand Oaks biotech giant and AbbVie, which owns the $16 billion per year Humira. U.S. sales of the biosimilar…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.